Kinda swamped today, but wanted to shine a light on a few noteworthy pieces:
A Kaiser Health News/Washington Post collaboration, “Concern Is Growing That The Elderly Get Too Many Medical Tests.”
Former Senate Finance Committee investigator Paul Thacker writes his first piece for Forbes, “How An Ethically Challenged Researcher Found A Home at the University of Miami.”
A long explainer – rare these days – by Marie McCullough of the Philadelphia Inquirer, “Cardiac gene therapy shows promise to save lives.” Excerpt:
“In recent months, researchers in Philadelphia and beyond have reported success using gene therapy to treat common, intractable cardiac problems including heart failure, hardened arteries, and the racing heartbeat known as atrial fibrillation.
You probably haven’t heard about these feats because they were in pigs, dogs, or sheep.
In the most complex mammal of all – humans – the results of cardiac gene therapy experiments have been encouraging, but inconclusive
….
The hopes – and the hurdles – are high.”
Opinions on other issues in news, journals, PR, advertising, marketing
Major revisions + reversals of reporting about the efficacy of remdesivir and HCQ have compromised the public's trust in scientists and physicians. Complexity and caution are key to public #COVID19 communications @garyschwitzer https://ja.ma/3fzUW0M
SPH adjunct associate professor @garyschwitzer presented to @Georgetown University public health students on how #covid19 has been "the perfect storm of politics, PR, and polluted messages to the public."
Watch the recorded zoom presentation here: https://www.healthnewsreview.org/2020/09/perfect-storm-of-politics-pr-polluted-messages-to-the-public/.
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Comments are closed.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like